Revolutionary Brain Biomarker: Early Psychosis Diagnosis Breakthrough

Researchers at the University of Rochester found a potential biomarker in the brain for diagnosing psychosis. This new approach may allow for earlier detection, offering better treatment options.

The study analyzed MRI scans from 159 participants, including 105 who developed psychotic disorders up to five years prior. The findings showed that participants with psychosis had weak connections between sensory regions in the cortex but stronger links to the thalamus, which relays information in the brain. These differences were identified in the somatomotor network, which deals with movement and sensations, and a visual network that processes objects and faces. By combining these connectivity patterns, researchers established a “somato-visual” biomarker.

Prior research indicated abnormalities in brain connectivity related to schizophrenia but did not clarify which networks were crucial or whether factors like medication, anxiety, or stress played a role.

Brian Keane, PhD, noted, “This biomarker stands out due to its significant effect size, its consistency across different conditions, and its reliability in multiple scans. A quick five-minute scan may help identify individuals at risk for transitioning to a psychotic disorder, enabling earlier interventions.”

The team aims to explore whether the somato-visual biomarker appears before psychosis begins. This study included contributions from researchers at Yale and Rutgers universities and was supported by grants from the University of Rochester.

For further information, refer to the study published in Molecular Psychiatry through the University of Rochester Medical Center.